Circulating omega-3 fatty acids and cardiometabolic outcomes: a systematic review of publications from UK Biobank
Circulating omega-3 fatty acids and cardiometabolic outcomes: a systematic review of publications from UK Biobank
Studies have shown that omega-3 fatty acids may protect against cardiovascular diseases (CVDs) and related metabolic conditions. UK Biobank is a large cohort study that includes data on plasma omega-3 fatty acids at study entry and health outcomes during the follow-up period. The aim of this research is to explore the association between plasma omega-3 fatty acids (total omega-3 fatty acids, docosahexaenoic acid (DHA) and non-DHA omega-3 fatty acids) and cardiometabolic health outcomes by systematically reviewing publications from UK Biobank. Three databases (EMBASE, MEDLINE, CINAHL) were searched in September 2025 using key words. Based on inclusion/exclusion criteria, 16 publications were selected for inclusion (two cross-sectional and 14 longitudinal with a follow-up of 11 to 14 years). Sample size varied between 20,338 and 273,834 across the included studies. Eleven studies reported on CVD outcomes and five on metabolic outcomes. Plasma total omega-3 fatty acids and DHA were inversely associated with risk of coronary heart disease, CVD mortality, heart failure, haemorrhagic stroke and severe fatty liver disease. Plasma total omega-3 fatty acids were also inversely associated with risk of prediabetes and type-2 diabetes, while plasma DHA was also inversely associated with risk of coronary heart disease mortality, ischemic stroke and fatty liver disease. It is concluded that publications based on UK Biobank consistently demonstrate a significant association between higher levels of total omega-3 fatty acids or DHA in plasma and lower likelihood of poor cardiometabolic health outcomes, providing support for guidance for the population to achieve recommended intakes of these fatty acids.
Eicosapentaenoic acid, cardiovascular disease, diabetes, docosahexaenoic acid, heart disease, liver disease
Tul Firdous, Warda
d22a789c-eaa3-40fd-87cc-399b7f70e3b3
Calder, Philip
1797e54f-378e-4dcb-80a4-3e30018f07a6
Tul Firdous, Warda
d22a789c-eaa3-40fd-87cc-399b7f70e3b3
Calder, Philip
1797e54f-378e-4dcb-80a4-3e30018f07a6
Tul Firdous, Warda and Calder, Philip
(2026)
Circulating omega-3 fatty acids and cardiometabolic outcomes: a systematic review of publications from UK Biobank.
Lipids.
(doi:10.1002/lipd.70076).
Abstract
Studies have shown that omega-3 fatty acids may protect against cardiovascular diseases (CVDs) and related metabolic conditions. UK Biobank is a large cohort study that includes data on plasma omega-3 fatty acids at study entry and health outcomes during the follow-up period. The aim of this research is to explore the association between plasma omega-3 fatty acids (total omega-3 fatty acids, docosahexaenoic acid (DHA) and non-DHA omega-3 fatty acids) and cardiometabolic health outcomes by systematically reviewing publications from UK Biobank. Three databases (EMBASE, MEDLINE, CINAHL) were searched in September 2025 using key words. Based on inclusion/exclusion criteria, 16 publications were selected for inclusion (two cross-sectional and 14 longitudinal with a follow-up of 11 to 14 years). Sample size varied between 20,338 and 273,834 across the included studies. Eleven studies reported on CVD outcomes and five on metabolic outcomes. Plasma total omega-3 fatty acids and DHA were inversely associated with risk of coronary heart disease, CVD mortality, heart failure, haemorrhagic stroke and severe fatty liver disease. Plasma total omega-3 fatty acids were also inversely associated with risk of prediabetes and type-2 diabetes, while plasma DHA was also inversely associated with risk of coronary heart disease mortality, ischemic stroke and fatty liver disease. It is concluded that publications based on UK Biobank consistently demonstrate a significant association between higher levels of total omega-3 fatty acids or DHA in plasma and lower likelihood of poor cardiometabolic health outcomes, providing support for guidance for the population to achieve recommended intakes of these fatty acids.
Text
Tul Firdous and Calder Manuscript_Revised Clean
- Accepted Manuscript
Text
Supplementary Table 1
- Accepted Manuscript
Image
Figure 1_revised
- Accepted Manuscript
More information
Accepted/In Press date: 22 July 2026
e-pub ahead of print date: 29 July 2026
Additional Information:
Publisher Copyright:
© 2026 The Author(s). Lipids published by Wiley Periodicals LLC on behalf of AOCS.
Keywords:
Eicosapentaenoic acid, cardiovascular disease, diabetes, docosahexaenoic acid, heart disease, liver disease
Identifiers
Local EPrints ID: 513527
URI: https://eprints.soton.ac.uk/id/eprint/513527
ISSN: 0024-4201
PURE UUID: 5ce97d99-90ea-49de-ae30-8a92d64addb3
Catalogue record
Date deposited: 19 Aug 2026 16:44
Last modified: 13 Sep 2026 15:50
Export record
Altmetrics
Contributors
Author:
Warda Tul Firdous
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics